Hyundai Bio and Korean Society for Urogenital Infections Sign MOU... Researcher Clinical Trial of 'CP-COV03' Targeting HPV

Lee Seung-joo, President of the Korean Society for Urogenital Infections (left), Oh Sang-gi, CEO of Hyundai Bio.

[Asia Economy Reporter Lee Gwan-joo] Hyundai Bio announced on the 29th that it has signed a memorandum of understanding (MOU) with the Korean Society for Genitourinary Infections to advance investigator-initiated clinical trials to verify the efficacy of the broad-spectrum antiviral candidate substance 'CP-COV03' for human papillomavirus (HPV) infection diseases.

HPV, which is mainly transmitted through sexual contact, causes warts on the genitalia or anus of both men and women, and subsequently can lead to genital cancers such as cervical cancer, vulvar cancer, and anal cancer. However, currently, there are only vaccines for HPV infection prevention, and no treatment drugs exist.

Hyundai Bio plans to provide clinical reagents free of charge for the investigator-initiated clinical trials conducted by the Korean Society for Genitourinary Infections. The clinical trials are expected to be led by the society president, Professor Lee Seung-joo of the Catholic University College of Medicine, and the academic director, Professor Lim Dong-hoon of the Department of Urology at Chosun University College of Medicine, along with other executives.

Professor Lim previously announced the plan for investigator-initiated clinical trials to confirm the therapeutic effect of CP-COV03 on HPV infections during the society's summer workshop held on the 27th at the Suwon Convention Center, in a presentation titled "Broad-spectrum Antiviral Niclosamide: From COVID-19 to HPV."

This content was produced with the assistance of AI translation services.